Radiolabeled Sodium Channel Imaging Agents
Solution Overview
Problem
Current methods are inadequate for measuring SCN5A density in patients and quantifying drug occupancy levels at NaV1.5, which is crucial for assessing cardiac function and response to therapies.
Innovation Solution
Development of radiolabeled compounds that selectively bind to SCN5A in the myocardium, allowing for imaging and monitoring of SCN5A and NaV1.5 levels, enabling effective drug targeting and treatment monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current imaging methods are used, then general cardiac imaging is possible, but SCN5A density measurement and drug occupancy quantification cannot be achieved
Solution Approach 1:
The patent introduces radiolabeled compounds as intermediary agents that specifically bind to SCN5A channels. These compounds act as mediators between the imaging system and the target protein, enabling indirect detection and quantification of SCN5A density and drug occupancy that cannot be achieved by direct measurement methods
Solution Approach 2:
The invention changes the measurement parameter from general cardiac structure imaging to specific molecular target imaging by using radiolabeled compounds with distinct radioactive signatures. This parameter change enables precise quantification of SCN5A density and drug occupancy at the molecular level
2Measurement precision
If radiolabeled compounds are developed for selective SCN5A binding, then imaging precision is improved, but device complexity increases
Solution Approach 1:
The radiolabeled compounds serve as intermediary agents that simplify the overall imaging system by providing specific molecular targeting. Rather than complicating the imaging device with complex molecular recognition systems, the complexity is transferred to the easily synthesizable radiolabeled ligands that can be administered systemically
3Loss of information
If selective radiolabeled compounds are used for SCN5A imaging, then drug occupancy quantification becomes possible, but manufacturing complexity increases
Solution Approach 1:
The radiolabeled compounds are designed with multi-functionality, serving both as imaging agents for SCN5A visualization and as quantification tools for drug occupancy assessment. This universal application reduces the need for multiple separate manufactured agents, simplifying the overall manufacturing process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise imaging and monitoring of SCN5A and NaV1.5 levels, facilitating improved therapeutic strategies for cardiovascular diseases by providing a means to assess expression density and drug efficacy.
Implementation Method 1
radiolabeled compounds that are useful for imaging voltage gated sodium channels
Data Source
AI summary
Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.